Terlipressin in brain-death donors
Related Experiment Video
Updated: May 17, 2026
Study of Experimental Organ Donation Models for Lung Transplantation
Published on: March 15, 2024
Ornella Piazza1, Giuliana Scarpati, Fabio Rispoli
1Anestesiologia e Rianimazione, Università degli Studi di Salerno, Baronissi, Salerno, Italy. opiazza@unisa.it
Background:
Metabolic management of brain-death organ donors includes correction of the hormonal perturbations that occur after cerebral death and impair circulatory function. Vasopressin is a hormone secreted by the posterior pituitary gland, which contributes to maintain systemic blood pressure by regulating urine secretion and small arteriole tonus. During brain death, the pituitary gland is damaged and hormone secretion rapidly ceases. Low-dose vasopressin increases systemic blood pressure and decreases the need for catecholamines in brain-dead organ donors but it is not available in many countries. Terlipressin is a synthetic analog of vasopressin characterized by greater selectivity for the V1 receptor than vasopressin. To date, the efficacy of terlipressin as a pressor agent in humans has been reported in a few studies.
Method:
Pharmacology and literature about the use of terlipressin in shock and in particularly in neurogenic shock following brain death is summarized and our personal experience is reported.
Results And Conclusion:
Terlipressin is helpful in controlling severe hypotension; its use allowed to reduce the infusion rate of norepinephrine about 50% in two of three brain-death organ donors, but there are not yet enough data to define its therapeutic range and incidence of collateral effects on the grafts.
